Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million plus royalties, adding the preclinical DBT‑3757 degrader directed at MLLT1 and MLLT3 and Dark Blue’s cancer discovery platform. The purchase brings Amgen an early‑stage small molecule that reportedly degraded oncogenic fusion partners active in acute leukemias and complements Amgen’s targeted‑degradation research. Targeted protein degradation selectively tags disease proteins for disposal rather than simply inhibiting them. The transaction expands Amgen’s oncology footprint in Europe and pairs the acquired programs with internal R&D capability to accelerate IND readiness and clinical entry. Industry sources said the deal is one of multiple European tie‑ups as Big Pharma seeks novel mechanisms to replenish oncology pipelines.